医学
肥胖
体质指数
内科学
肿瘤科
免疫疗法
癌症
临床试验
不利影响
肥胖悖论
超重
作者
Alice Indini,Erika Rijavec,Michele Ghidini,Gianluca Tomasello,Monica Cattaneo,F. Barbin,Claudia Bareggi,Barbara Galassi,Donatella Gambini,Francesco Grossi
摘要
Growing research has focused on obesity as a prognostic factor during therapy with immune-checkpoint inhibitors (ICIs). The role of body-mass index (BMI) in predicting response and toxicity to ICIs is not clear, as studies have shown inconsistent results and significant interpretation biases. We performed a systematic review to evaluate the relationship between BMI and survival outcomes during ICIs, with a side focus on the incidence of immune-related adverse events (irAEs). A total of 17 studies were included in this systematic review. Altogether, the current evidence does not support a clearly positive association of BMI with survival outcomes. Regarding toxicities, available studies confirm a superimposable rate of irAEs among obese and normal weight patients. Intrinsic limitations of the analyzed studies include the retrospective nature, the heterogeneity of patients’ cohorts, and differences in BMI categorization for obese patients across different studies. These factors might explain the heterogeneity of available results, and the subsequent absence of a well-established role of baseline BMI on the efficacy of ICIs among cancer patients. Further prospective studies are needed, in order to clarify the role of obesity in cancer patients treated with immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI